Up­dat­ed: FDA ap­proves Pfiz­er’s Pre­vnar 20 for in­fants and chil­dren

Pfiz­er has se­cured ap­proval from the FDA for its Pre­vnar 20 pneu­mo­coc­cal dis­ease vac­cine for in­fants, chil­dren and ado­les­cents, the New York-based drug­mak­er an­nounced Thurs­day.

The ap­proval will al­low the vac­cine to be used in in­fants as young as 6 weeks. It was al­ready ap­proved for adults.

Pre­vnar 20 is de­signed to pre­vent in­va­sive pneu­mo­coc­cal dis­ease and was based on re­sults from Pfiz­er’s Phase III tri­als that hit their pri­ma­ry ob­jec­tives back in 2022. The vac­cine is a suc­ces­sor to Pfiz­er’s 13-va­lent vac­cine, and to­geth­er the shots have sold bil­lions of dol­lars and are among the com­pa­ny’s biggest prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER